Odomzo

Description

The FDA has approved Novartis’ Odomzo to treat locally advanced basal cell carcinoma in adults. The drug is approved for use in patients whose tumors have recurred after surgery or radiation therapy, as well as for use in patients who are not candidates for surgery or radiation therapy.

Odomzo (sonidegib) is an inhibitor of the Hedgehog signaling pathway. Inhibition of this pathway can stop or reduce the growth of cancer.

Active ingredient: sonidegib

Prescription medicine